Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.…
PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
Lucid Diagnostics (NASDAQ: LUCD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 82 employees.
The shares were at 0.3727 USD on 20 November 2026, down 65.5% over 52 weeks. Its 52-week range is 0.3030 USD to 1.629 USD: the price is 77.1% below the high and 23.0% above the low.
Its market capitalisation is 72.57M USD.
Lucid Diagnostics reports revenue down 0.7% year over year.
It holds more cash than debt, a net cash position of 542.00K USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 24 March 2027.